Latest 30 News in the Life Sciences Industry
PR Newswire Association LLC.
Driving Community Health: Bristol Myers Squibb, Emirates Thalassemia Society and Dubai Science Park Host the 6th 'Help Save a Life' Blood Donation Drive
05 Oct 2026
PR Newswire Association LLC.
West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
05 Oct 2026
PR Newswire Association LLC.
SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026
04 Oct 2026
PR Newswire Association LLC.
19.3% Weight Loss at Week 48: Phase Ⅲ Data of Olatorepatide, Hansoh's Dual‑Biased GLP‑1/GIP Agonist, Presented at EASD
02 Oct 2026
PR Newswire Association LLC.
ADAMA Launches Botanical Fungicide Actavan® in Australia and New Zealand
01 Oct 2026
PR Newswire Association LLC.
AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026
30 Sep 2026
PR Newswire Association LLC.
Newronika Announces First Participant Implanted in ADVENT Pivotal Study
30 Sep 2026
PR Newswire Association LLC.
Sinocare Showcases Integrated Chronic Disease Management Solutions at EASD 2026
30 Sep 2026
PR Newswire Association LLC.
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
29 Sep 2026
PR Newswire Association LLC.
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
29 Sep 2026
PR Newswire Association LLC.
UCSF Benioff Children's Hospitals Become the First US Qualified Treatment Center Contracted to Administer Individualized Gene Therapy WASKYRA®
28 Sep 2026
PR Newswire Association LLC.
Tethis, MACS and Everex announce transfer of See.d® business unit and long-term manufacturing partnership
21 Sep 2026
PR Newswire Association LLC.
Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
21 Sep 2026
PR Newswire Association LLC.
Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site
16 Sep 2026
PR Newswire Association LLC.
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
15 Sep 2026
GlobeNewswire
Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada
05 Aug 2026
GlobeNewswire
Italfarmaco Announces Managed Entry Agreement in Georgia for Givinostat as Treatment for Patients with Duchenne Muscular Dystrophy
31 Jul 2026
GlobeNewswire
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
31 Jul 2026
GlobeNewswire
AGC Biologics Lands Commercial Manufacturing Agreement for Yokohama Site Worth Hundreds of Millions of Dollars
28 Jul 2026
GlobeNewswire
RECORDATI: SOLID MOMENTUM OF THE GROUP CONTINUES FIRST HALF 2026. NET REVENUE +6.6%, EBITDA +8.8%, ADJUSTED NET INCOME +6.7%
28 Jul 2026
GlobeNewswire
NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease
24 Jul 2026
GlobeNewswire
Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm
23 Jul 2026
GlobeNewswire
AAVantgarde Announces Participation of Founder and CSO, Prof. Alberto Auricchio at the 32nd Annual Meeting of the Japanese Society for Gene and Cell Therapy
23 Jul 2026
GlobeNewswire
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
21 Jul 2026
GlobeNewswire
Nouscom Selected for Oral Presentation on NOUS-209 Re-treatment and Long-Term Follow-Up in Lynch Syndrome Carriers at ESMO Congress 2026
20 Jul 2026
GlobeNewswire
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
17 Jul 2026
Upcoming Events All Events
- October 2026
- Milan: CPHI Milan 2026
- Basel: 26th Annual Biotech in Europe Forum
- Yokohama: BioJapan